<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33550390</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Cycad Genotoxin Methylazoxymethanol Disrupts the Brain Ubiquitin-Proteasome Pathway, Tau and &#x3b1;-Synuclein, as Reported in ALS-PDC.</ArticleTitle><Pagination><StartPage>286</StartPage><EndPage>288</EndPage><MedlinePgn>286-288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlab006</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kisby</LastName><ForeName>Glen E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Pharmacology, Western University for Health Sciences, Lebanon, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksen</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Pharmacology, University of Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chlebowski</LastName><ForeName>Anna C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Pharmacology, Western University for Health Sciences, Lebanon, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Neurology, School of Medicine and Oregon Institute of Occupational Health Sciences, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 ES011384</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009153">Mutagens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>592-62-1</RegistryNumber><NameOfSubstance UI="D008746">Methylazoxymethanol Acetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>JGG19N3YDQ</RegistryNumber><NameOfSubstance UI="C030667">methylazoxymethanol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029784" MajorTopicYN="Y">Cycas</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008746" MajorTopicYN="N">Methylazoxymethanol Acetate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009153" MajorTopicYN="N">Mutagens</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>20</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33550390</ArticleId><ArticleId IdType="pmc">PMC8786491</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlab006</ArticleId><ArticleId IdType="pii">6130087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Verheijen BM, Morimoto S, Sasaki R, et al. &#xa0;Expression of mutant ubiquitin and proteostasis impairment in Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex brains. J Neuropathol Exp Neurol &#xa0;2020;79:902&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">32647880</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen BM, Lussier C, M&#xfc;ller-H&#xfc;bers C, et al. &#xa0;Activation of the unfolded protein response and proteostasis disturbance in parkinsonism-dementia of Guam. J Neuropathol Exp Neurol &#xa0;2020;79:34&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pubmed">31750913</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen BM, Hashimoto T, Oyanagi K, et al. &#xa0;Deposition of mutant ubiquitin in parkinsonism-dementia complex of Guam. Acta Neuropathol Commun &#xa0;2017;5:82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679492</ArticleId><ArticleId IdType="pubmed">29122008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisby GE, Spencer PS. &#xa0;Is neurodegenerative disease a long-latency response to early-life genotoxin exposure? &#xa0;Int J Environ Res Public Health &#xa0;2011;8:3889&#x2013;921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3210588</ArticleId><ArticleId IdType="pubmed">22073019</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer PS, Palmer VS, Kihira T, et al. &#xa0;Kamp&#x14d; medicine and Muro disease (Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex. eNeurologicalSci &#xa0;2020;18:100230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7026288</ArticleId><ArticleId IdType="pubmed">32090178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisby GE, Ellison M, Spencer PS. &#xa0;Content of the neurotoxins cycasin (methylazoxymethanol &#x3b2;-d-glucoside) and BMAA (&#x3b2;-N-methylamino-l-alanine) in cycad flour prepared by Guam Chamorros. Neurology &#xa0;1992;42:1336&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">1620343</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC. &#xa0;Neuroepidemiology of amyotrophic lateral sclerosis: Clues to aetiology and pathogenesis. J Neurol Neurosurg Psychiatry &#xa0;1996;61:131&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1073984</ArticleId><ArticleId IdType="pubmed">8708678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman GR, Crowley DJ, Thophiles PJ. &#xa0;Comparative potencies of induction of point mutations and genetic duplications by the methylating agents methylazoxymethanol and dimethyl sulfate in bacteria. Mutagenesis &#xa0;2002;439&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">12202633</ArticleId></ArticleIdList></Reference><Reference><Citation>Esclaire F, Kisby G, Spencer P, et al. &#xa0;The Guam cycad toxin methylazoxymethanol damages neuronal DNA and modulates tau mRNA expression and excitotoxicity. Exp Neurol &#xa0;1999;155:11&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">9918700</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer PS. &#xa0;Etiology of retinal and cerebellar pathology in Western Pacific Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex. Eye Brain &#xa0;2020;12:97&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381794</ArticleId><ArticleId IdType="pubmed">32765151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisby GE, Standley M, Lu X, et al. &#xa0;Molecular networks perturbed in a developmental animal model of brain injury. Neurobiol Dis &#xa0;2005;19:108&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">15837566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisby GE, Olivas A, Park T, et al. The cycad genotoxicant methylazoxymethanol (MAM) disrupts tau metabolism and increases tau phosphorylation during early brain development. Society for Neuroscience Abstr. #439.27, 2008.</Citation></Reference><Reference><Citation>Morimoto S, Hatsuta H, Kokubo Y, et al. &#xa0;Unusual tau pathology of the cerebellum in patients with amyotrophic lateral sclerosis/parkinsonism-dementia complex from the Kii Peninsula, Japan. Brain Pathol &#xa0;2018;28:287&#x2013;91</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028275</ArticleId><ArticleId IdType="pubmed">28236345</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisby GE, Standley T, Park A, et al. &#xa0;Proteomic analysis of the genotoxicant methylazoxymethanol (MAM)-induced changes in the developing cerebellum. J Proteome Res &#xa0;2006;5:2656&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">17022636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Woltjer RL, Sokal I, et al. &#xa0;Quantitative proteomics identifies surfactant-resistant &#x3b1;-synuclein in cerebral cortex of Parkinsonism-Dementia Complex of Guam but not Alzheimer&#x2019;s Disease or progressive supranuclear palsy. Am J Pathol &#xa0;2007;171:993&#x2013;1002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1959487</ArticleId><ArticleId IdType="pubmed">17675576</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N, Duff KE. &#xa0;Targeting the 26S proteasome to protect against proteotoxic diseases. Trends Mol Med &#xa0;2018;24:18&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5905406</ArticleId><ArticleId IdType="pubmed">29233753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>